BioSpecifics Technologies Corp. (BSTC) Analysts See $0.39 EPS; Fiduciary (FMO) Sentiment Is 1.38

February 15, 2018 - By Matt Maslow

Analysts expect BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report $0.39 EPS on March, 21.They anticipate $0.01 EPS change or 2.50% from last quarter’s $0.4 EPS. BSTC’s profit would be $2.80 million giving it 25.48 P/E if the $0.39 EPS is correct. After having $0.37 EPS previously, BioSpecifics Technologies Corp.’s analysts see 5.41% EPS growth. The stock decreased 0.38% or $0.15 during the last trading session, reaching $39.75. About 34,512 shares traded or 32.96% up from the average. BioSpecifics Technologies Corp. (NASDAQ:BSTC) has risen 49.91% since February 15, 2017 and is uptrending. It has outperformed by 33.21% the S&P500.

Fiduciary/Claymore MLP Opportunity Fund is a closed ended equity mutual fund launched and managed by Guggenheim Funds Investment Advisors, LLC. The company has market cap of $467.81 million. It is co-managed by Advisory Research, Inc. It has a 12.62 P/E ratio. The fund invests in the public equity markets of the United States.




BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has market cap of $285.77 million. The firm offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It has a 25 P/E ratio. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids.

Among 2 analysts covering BioSpecifics Technologies Corp (NASDAQ:BSTC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioSpecifics Technologies Corp had 6 analyst reports since March 8, 2016 according to SRatingsIntel. H.C. Wainwright maintained BioSpecifics Technologies Corp. (NASDAQ:BSTC) on Monday, November 13 with “Buy” rating. The firm has “Buy” rating given on Wednesday, February 7 by H.C. Wainwright. The firm has “Buy” rating by Rodman & Renshaw given on Tuesday, March 8. On Thursday, August 10 the stock rating was maintained by H.C. Wainwright with “Buy”. On Monday, December 11 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, December 26.

Investors sentiment decreased to 1.08 in Q3 2017. Its down 0.15, from 1.23 in 2017Q2. It dived, as 10 investors sold BioSpecifics Technologies Corp. shares while 27 reduced holdings. 16 funds opened positions while 24 raised stakes. 3.70 million shares or 3.67% less from 3.84 million shares in 2017Q2 were reported. Vanguard Grp Inc invested 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Chicago Equity Ptnrs Limited Liability reported 0.02% in BioSpecifics Technologies Corp. (NASDAQ:BSTC). First Manhattan holds 0.01% or 35,180 shares in its portfolio. Bancshares Of Montreal Can holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 5,537 shares. Ajo Limited Partnership holds 0% or 10,951 shares in its portfolio. Royal Savings Bank Of Canada has 430 shares. American Century Incorporated reported 25,607 shares. Northern Trust holds 0% of its portfolio in BioSpecifics Technologies Corp. (NASDAQ:BSTC) for 86,094 shares. Hanson Mcclain Incorporated owns 200 shares for 0% of their portfolio. Mutual Of America Capital Management Ltd Liability reported 52,811 shares. Renaissance Technology Lc accumulated 415,300 shares or 0.02% of the stock. Moreover, Wellington Mgmt Gp Limited Liability Partnership has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Sg Americas Secs Ltd Liability Com has 0% invested in BioSpecifics Technologies Corp. (NASDAQ:BSTC). Aqr Cap Mngmt Ltd Co holds 0.01% or 116,867 shares. 3,266 were accumulated by Nationwide Fund Advsr.

Jacobus Wealth Management Inc. holds 0.91% of its portfolio in Fiduciary/Claymore MLP Opportunity Fund for 268,673 shares. Truenorth Inc. owns 59,644 shares or 0.36% of their US portfolio. Moreover, Sit Investment Associates Inc has 0.26% invested in the company for 814,759 shares. The Illinois-based Optimum Investment Advisors has invested 0.17% in the stock. Advisors Asset Management Inc., a Colorado-based fund reported 507,622 shares.

The stock decreased 1.70% or $0.23 during the last trading session, reaching $13.23. About 249,288 shares traded. Fiduciary/Claymore MLP Opportunity Fund (FMO) has risen 15.54% since February 15, 2017 and is uptrending. It has underperformed by 1.16% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.